Project Grant K99HL188111
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $105K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Northwestern University $1,589,058 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 25, 2026, to support research on disordered mitochondrial proteostasis and alveolar epithelial repair in aging lungs. The project investigates how age-related dysfunction in mitochondrial complex I impairs lung recovery following viral pneumonia, with a focus on the role of alveolar epithelial type 2 cells in epithelial repair and the...
- The National Heart Lung and Blood Institute awarded Northwestern University $654,762 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory T cell mechanisms limiting persistent inflammation during recovery from viral pneumonia. The award funds research into how FOXP3+ regulatory T cells orchestrate lung repair after viral pneumonia through expression of suppressive mediators, particularly the anti-inflammatory cytokine interleukin-10. The...
- The National Heart, Lung, and Blood Institute awarded Northwestern University a project grant of $793,976 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate bone morphogenetic protein and connexin40 signaling as regulators of endothelial quiescence in lung transplantation. The research addresses primary graft dysfunction, an acute lung injury driven by ischemia-reperfusion injury that limits lung transplantation success. The project will...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $2,162,045 under Cardiovascular Diseases Research (CFDA 93.837) on September 15, 2025, for research characterizing apolipoprotein proteoforms and their relationships with cardiometabolic health and coronary heart disease events. The research objective is to characterize the full spectrum of apolipoprotein post-translational modifications in human plasma and to quantify their associations with adiposity, insulin...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $346,960 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 20, 2025, to investigate the inflammatory-fibrotic axis in advanced pulmonary sarcoidosis-related fibrosis (APSF). The research applies single-cell RNA sequencing (scRNA-seq) and surface protein indexing to identify key regulators and signaling pathways within CD14+ monocyte subpopulations in individuals with chronic...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $670,622 as a Project Grant (R01HL180941) on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of endogenous RNA sensing in the amplification of lung injury. The research focuses on how lung infections induce widespread lung vascular endothelial injury through a cycle of endothelial barrier breakdown and inflammatory cell influx. The project...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $163,836 on July 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research into the cellular and molecular pathways that drive pulmonary silicosis. The research dissects bidirectional signaling networks between fibroblasts and macrophages in silica-induced granulomatous lung injury. Preliminary single-cell RNA sequencing identified...